These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Effects of cromakalim and glibenclamide on myocardial high energy phosphates and intracellular pH during ischemia-reperfusion: 31P NMR studies. Docherty JC; Gunter HE; Kuzio B; Shoemaker L; Yang L; Deslauriers R J Mol Cell Cardiol; 1997 Jun; 29(6):1665-73. PubMed ID: 9220352 [TBL] [Abstract][Full Text] [Related]
5. K(ATP)-channel activation: effects on myocardial recovery from ischaemia and role in the cardioprotective response to adenosine A1-receptor stimulation. Ford WR; Lopaschuk GD; Schulz R; Clanachan AS Br J Pharmacol; 1998 Jun; 124(4):639-46. PubMed ID: 9690854 [TBL] [Abstract][Full Text] [Related]
6. Potassium channel blockade of atrial negative inotropic responses to P1-purinoceptor and muscarinic receptor agonists and to cromakalim. Urquhart RA; Ford WR; Broadley KJ J Cardiovasc Pharmacol; 1993 Feb; 21(2):279-88. PubMed ID: 7679163 [TBL] [Abstract][Full Text] [Related]
7. Effect of potassium channel blockade on the anti-ischemic actions of mechanistically diverse agents. Sargent CA; Smith MA; Dzwonczyk S; Sleph PG; Grover GJ J Pharmacol Exp Ther; 1991 Oct; 259(1):97-103. PubMed ID: 1920138 [TBL] [Abstract][Full Text] [Related]
11. Pharmacologic characterization of BMS-191095, a mitochondrial K(ATP) opener with no peripheral vasodilator or cardiac action potential shortening activity. Grover GJ; D'Alonzo AJ; Garlid KD; Bajgar R; Lodge NJ; Sleph PG; Darbenzio RB; Hess TA; Smith MA; Paucek P; Atwal KS J Pharmacol Exp Ther; 2001 Jun; 297(3):1184-92. PubMed ID: 11356945 [TBL] [Abstract][Full Text] [Related]
12. Hypoxic preconditioning in isolated rat hearts: non-involvement of activation of adenosine A1 receptor, Gi protein, and ATP-sensitive K+ channel. Yabe K; Nasa Y; Takeo S Heart Vessels; 1995; 10(6):294-303. PubMed ID: 8655466 [TBL] [Abstract][Full Text] [Related]
13. The KATP blocker sodium 5-hydroxydecanoate does not abolish preconditioning in isolated rat hearts. Grover GJ; Murray HN; Baird AJ; Dzwonczyk S Eur J Pharmacol; 1995 Apr; 277(2-3):271-4. PubMed ID: 7493619 [TBL] [Abstract][Full Text] [Related]
14. Cardioprotective effects of the potassium channel opener cromakalim: stereoselectivity and effects on myocardial adenine nucleotides. Grover GJ; Newburger J; Sleph PG; Dzwonczyk S; Taylor SC; Ahmed SZ; Atwal KS J Pharmacol Exp Ther; 1991 Apr; 257(1):156-62. PubMed ID: 2019983 [TBL] [Abstract][Full Text] [Related]
15. Protective effect of K(ATP) openers in ischemic rat hearts treated with a potassium cardioplegic solution. Grover GJ; Sleph PG J Cardiovasc Pharmacol; 1995 Nov; 26(5):698-706. PubMed ID: 8637183 [TBL] [Abstract][Full Text] [Related]
16. Potassium channel openers and blockers: do they possess proarrhythmic or antiarrhythmic activity in ischemic and reperfused rat hearts? Tosaki A; Szerdahelyi P; Engelman RM; Das DK J Pharmacol Exp Ther; 1993 Dec; 267(3):1355-62. PubMed ID: 8263798 [TBL] [Abstract][Full Text] [Related]
17. Cardioprotection in ischemic rat hearts with the SH-containing angiotensin-converting enzyme inhibitor zofenopril: possible involvement of the ATP-sensitive potassium channel. Sargent CA; Sleph PG; Dzwonczyk S; Smith MA; Normandin D; Antonaccio MJ; Grover GJ J Pharmacol Exp Ther; 1993 May; 265(2):609-18. PubMed ID: 8496812 [TBL] [Abstract][Full Text] [Related]
18. Anti-ischemic effects of the potassium channel activators pinacidil and cromakalim and the reversal of these effects with the potassium channel blocker glyburide. Grover GJ; McCullough JR; Henry DE; Conder ML; Sleph PG J Pharmacol Exp Ther; 1989 Oct; 251(1):98-104. PubMed ID: 2507775 [TBL] [Abstract][Full Text] [Related]
19. Diabetes and ATP-sensitive potassium channel openers and blockers in isolated ischemic/reperfused hearts. Tosaki A; Engelman DT; Engelman RM; Das DK J Pharmacol Exp Ther; 1995 Dec; 275(3):1115-23. PubMed ID: 8531071 [TBL] [Abstract][Full Text] [Related]
20. KATP channel modulation in working rat hearts with coronary occlusion: effects of cromakalim, cicletanine, and glibenclamide. Ferdinandy P; Szilvássy Z; Droy-Lefaix MT; Tarrade T; Koltai M Cardiovasc Res; 1995 Nov; 30(5):781-7. PubMed ID: 8595627 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]